Search
Lesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnMarketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target … In August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with
Enoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigational[L31393] Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding. … Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders.
Products: LOVENOX 10.000 IE (100 mg)/1 ml Injektionslösung in einer Fertigspritze, LOVENOX 15.000 IE (150 mg)/1 ml Injektionslösung in einer FertigspritzeMyrrh
go.drugbank.com/drugs/DB11605ApprovedInvestigationalExtractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora abyssinica, Burseraceae.
Categories: Complex MixturesHexylcaine
go.drugbank.com/drugs/DB00473ApprovedWithdrawnHexylcaine has been discontinued in the US market. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.
Cefroxadine
go.drugbank.com/drugs/DB11367ApprovedWithdrawnIt was used in Italy but has since been withdrawn. … Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to [cefalexin] as well as its activity spectrum.
Mepyramine
go.drugbank.com/drugs/DB06691ApprovedVet approvedIt has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.
Synonyms: N-(p-methoxybenzyl)-N',N'-dimethyl-N-(α-pyridyl)ethylenediamine, N',N'-dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamineLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnNew Zealand and Canada have also followed suit in recalling the drug. … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Diethylamino hydroxybenzoyl hexyl benzoate
go.drugbank.com/drugs/DB11269ApprovedIt is used in concentrations up to 10% in sunscreen products, either alone or in combination with other UV absorbers [F107]. … Diethylamino hydroxybenzoyl hexyl benzoate was approved in Europe in 2005, and is also marketed in the U.S., South America, Mexico, Japan and Taiwan.
Aflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [L47915] All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including
Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL